Trisubstituted-Imidazoles Induce Apoptosis in Human Breast Cancer Cells by Targeting the Oncogenic PI3K/Akt/mTOR Signaling Pathway
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Overactivation of PI3K/Akt/mTOR is linked with carcinogenesis and serves a potential molecular therapeutic target in treatment of various cancers. Herein, we report the synthesis of trisubstituted-imidazoles and identified 2-chloro-3-(4, 5-diphenyl-1H-imidazol-2-yl) pyridine (CIP) as lead cytotoxic agent. Naïve Base classifier model of in silico target prediction revealed that CIP targets RAC-beta serine/threonine-protein kinase which comprises the Akt. Furthermore, CIP downregulated the phosphorylation of Akt, PDK and mTOR proteins and decreased expression of cyclin D1, Bcl-2, survivin, VEGF, procaspase-3 and increased cleavage of PARP. In addition, CIP significantly downregulated the CXCL12 induced motility of breast cancer cells and molecular docking calculations revealed that all compounds bind to Akt2 kinase with high docking scores compared to the library of previously reported Akt2 inhibitors. In summary, we report the synthesis and biological evaluation of imidazoles that induce apoptosis in breast cancer cells by negatively regulating PI3K/Akt/mTOR signaling pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
ChEMBL: a large-scale bioactivity database for drug discovery
Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr777 · Cited by 4,382 · cited 2×
“Active compounds were extracted from ChEMBL [34], using pChEMBL values larger than 5 (10 μM) and a confidence score cut-off of 5 to define activity.”
MethodCellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises
Yap, T. A., Garrett, M. D., Walton, M. I., Raynaud, F., de Bono, J. S., & Workman, P. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.08.004 · Cited by 543
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Self-citationEmerging role of exosomes in cancer progression and tumor microenvironment remodeling
Paskeh, M. D. A., Entezari, M., Mirzaei, S., Zabolian, A., Saleki, H., Naghdi, M. J., Sabet, S., Khoshbakht, M. A., Hashemi, M., Hushmandi, K., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01305-4 · Cited by 563
Self-citationEndophytic Fungi—Alternative Sources of Cytotoxic Compounds: A Review
Uzma, F., Mohan, C. D., Hashem, A., Konappa, N. M., Rangappa, S., Kamath, P. V., Singh, B. P., Mudili, V., Gupta, V. K., Siddaiah, C. N., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00309 · Cited by 293
Self-citationTherapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
Mirzaei, S., Saghari, S., Bassiri, F., Raesi, R., Zarrabi, A., Hushmandi, K., Sethi, G., & Tergaonkar, V. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30759 · Cited by 243
“Therefore, inhibition of PI3K/Akt signaling can be beneficial in impairing tumor progression (Mohan et al., 2016).”
BackgroundSelf-citationMirzaei, S., Zarrabi, A., Hashemi, F., Zabolian, A., Saleki, H., Ranjbar, A., Seyed Saleh, S. H., Bagherian, M., Sharifzadeh, S. O., Hushmandi, K., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.03.025 · Cited by 224
Self-citationParama, D., Boruah, M., Yachna, K., Rana, V., Banik, K., Harsha, C., Thakur, K. K., Dutta, U., Arya, A., Mao, X., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118182 · Cited by 155
Celastrol in cancer therapy: Recent developments, challenges and prospects
Lim, H. Y., Ong, P. S., Wang, L., Goel, A., Ding, L., Li-Ann Wong, A., Ho, P. C.-L., Sethi, G., Xiang, X., & Goh, B. C. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.030 · Cited by 118
Self-citation
Metadata
- Authors
- Mohan, C. D., Srinivasa, V., Rangappa, S., Mervin, L., Mohan, S., Paricharak, S., Baday, S., Li, F., Shanmugam, M. K., Chinnathambi, A., Zayed, M. E., Alharbi, S. A., Bender, A., Sethi, G., Basappa, & Rangappa, K. S.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-04-20
- Volume
- 11
- Issue
- 4
- Pages
- e0153155
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2336661473
- Cited by
- 130
- References
- 4
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.